| Print
Aptorum Group Limited (APM)
Ordinary SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Aptorum Group Ltd Annual Report for 2025 | 2026-04-30T00:00:00 |
| Aptorum Group Ltd Annual General Meeting for 2025 | 2026-02-06T21:00:00 |
| Aptorum Group Ltd Second Quarter Earnings Results for 2025 | 2026-02-06T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Aptorum Group Ltd Annual General Meeting for 2025 | 2026-02-06T21:00:00 |
| Aptorum Group Ltd Second Quarter Earnings Results for 2025 | 2026-02-06T00:00:00 |
| Aptorum Group Ltd Annual Report for 2024 | 2025-04-30T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.